Checkpoint Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.192 million compared to USD 0.268 million a year ago. Net loss was USD 62.62 million compared to USD 56.67 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | -0.96% | +6.70% | -9.61% |
06-24 | Checkpoint Therapeutics Plans to Resubmit Application for Cancer Treatment Candidate | MT |
06-24 | Checkpoint Therapeutics Reaches BLA Alignment With FDA for Cosibelimab | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.61% | 77.02M | |
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |
- Stock Market
- Equities
- CKPT Stock
- News Checkpoint Therapeutics, Inc.
- Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022